37.2 Feminizing Hormonal Therapy

Feminizing Hormonal Therapy

Feminizing hormonal therapy uses estrogens and anti-androgens to promote feminine secondary sexual characteristics while suppressing masculine traits. It's a core component of gender-affirming care, and nurses need to understand these medications thoroughly because they're responsible for baseline assessments, ongoing monitoring, patient education, and recognizing potentially serious side effects like venous thromboembolism and hyperkalemia.

Feminizing Hormonal Drugs

Two main drug classes work together in feminizing therapy: estrogens develop feminine characteristics, and anti-androgens block or reduce masculine ones.

Estrogens promote feminine characteristics and suppress testosterone production:

• Estradiol is the primary estrogen used. It's available as oral tablets, transdermal patches, and injectable forms. Transdermal and injectable routes are generally preferred because they bypass first-pass liver metabolism, which lowers the risk of thromboembolism and liver-related side effects.
• Conjugated estrogens are an alternative to estradiol but are used less frequently due to a less favorable safety profile.

Anti-androgens block or reduce the effects of testosterone:

• Spironolactone is the most commonly used anti-androgen in the U.S. It works as an androgen receptor antagonist and weakly inhibits testosterone synthesis. Originally a potassium-sparing diuretic, so hyperkalemia is a key concern.
• Cyproterone acetate is an androgen receptor antagonist with progestogenic activity. It's widely used outside the U.S. but is not FDA-approved in the United States due to hepatotoxicity risk.
• Finasteride and dutasteride are 5α-reductase inhibitors that prevent testosterone from converting to dihydrotestosterone (DHT). They're more targeted and are sometimes used as adjuncts rather than primary anti-androgens.
• GnRH agonists (leuprolide, goserelin) work by initially stimulating, then desensitizing GnRH receptors. This suppresses gonadotropin secretion (LH and FSH), which in turn reduces testosterone production. They're highly effective but expensive.

Progesterone is sometimes added and may enhance breast development, though evidence for this remains limited and its routine use is debated.

Mechanisms of Action and Side Effects

Estrogens

Estrogens bind to estrogen receptors throughout the body, promoting development of feminine secondary sexual characteristics: breast growth, redistribution of body fat to hips and thighs, softening of skin, and reduced body hair growth. They also suppress testosterone production through negative feedback on the hypothalamic-pituitary-gonadal (HPG) axis: higher estrogen levels signal the hypothalamus and pituitary to reduce GnRH, LH, and FSH release, which lowers gonadal testosterone output.

Potential side effects to monitor:

• Venous thromboembolism (VTE): the most serious risk, especially with oral estrogens and in patients who smoke
• Hypertriglyceridemia
• Gallstones
• Elevated liver enzymes
• Increased breast cancer risk with long-term use

Anti-androgens (by drug)

A few things worth highlighting: spironolactone requires regular potassium and renal function monitoring. Cyproterone acetate requires liver function monitoring. GnRH agonists cause an initial testosterone flare before suppression occurs, which patients should be warned about. Long-term GnRH agonist use also requires bone density screening (DEXA scans).

Nursing Considerations

Baseline assessment before starting therapy:

1. Obtain a thorough medical history, including personal and family history of VTE, liver disease, cardiovascular disease, and hormone-sensitive cancers.
2. Perform a physical examination including blood pressure, weight, and breast exam.
3. Order baseline laboratory tests: liver function tests, lipid profile, electrolytes (especially potassium if starting spironolactone), fasting glucose, and hormone levels (testosterone, estradiol).

Ongoing monitoring:

• Schedule regular follow-up visits, typically every 3 months in the first year, then every 6–12 months.
• Repeat laboratory tests periodically to track hormone levels, electrolytes, liver function, and lipids.
• Perform breast cancer screening per current guidelines.
• Monitor bone density if the patient is on GnRH agonists long-term.

Medication administration:

• Verify proper dosing and route at each visit.
• For injectable forms, teach and observe self-injection technique, including site rotation, aseptic technique, and proper needle disposal.
• For transdermal patches, educate on placement (clean, dry, hairless skin; rotate sites) and what to do if a patch falls off.

Psychosocial support:

• Assess mental health at each visit. Gender dysphoria, anxiety, and depression are common, and changes during transition can be emotionally intense.
• Collaborate with mental health professionals, endocrinologists, and primary care providers as part of an interdisciplinary team.
• Connect patients with support groups and community resources.

Patient Education Plan

Pre-treatment education:

• Discuss expected feminizing effects and realistic timelines. Breast development typically begins within 3–6 months but may take 2–3 years to reach full effect. Body fat redistribution, skin softening, and reduced body hair also develop gradually.
• Review potential side effects and serious risks, particularly VTE. Make sure the patient understands warning signs: leg swelling/pain, sudden shortness of breath, chest pain.
• Discuss fertility preservation options before starting treatment. Estrogens and anti-androgens can impair fertility, and these effects may not be fully reversible. Patients should be counseled about sperm banking if future biological children are desired.
• Emphasize the importance of regular follow-up and lab monitoring.

Medication education:

• Provide clear written instructions on dosing, administration, and storage for each prescribed medication.
• Demonstrate self-injection technique if applicable, and have the patient return-demonstrate.
• Teach patients which adverse reactions require immediate medical attention (signs of DVT/PE, severe abdominal pain suggesting liver issues, chest pain).

Lifestyle modifications:

• Encourage a healthy diet and regular exercise to maintain optimal weight and reduce cardiovascular risk, which is already elevated with estrogen therapy.
• Strongly counsel on smoking cessation. Smoking combined with estrogen therapy significantly increases VTE risk.
• Discuss alcohol moderation, particularly for patients on medications with hepatotoxicity risk.
• Advise on skin care and sun protection, as estrogen therapy can increase skin sensitivity.

Long-term considerations:

• Feminizing hormone therapy is typically lifelong. Even after gonadectomy, estrogen replacement is needed to prevent bone loss and other effects of hormone deficiency.
• Encourage open, ongoing communication with the healthcare team about any concerns, new symptoms, or changes in goals of care.
• Reinforce that dose adjustments are normal and expected as the team works toward target hormone levels.